{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-061371","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.721076+00:00","generated_at":"2026-05-18T23:58:58.279295+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PBFT02 Phase 1/2 data: durable PGRN boost; new pulmonary embolism SAE, protocol to add anticoagulation","bullets":["Dose 1 PBFT02 increased CSF PGRN from <3 ng/mL to mean 25.9 ng/mL at 12 months (n=4); Dose 2 patient rose to 7.6 ng/mL at 1 month.","Plasma NfL increased only 4% in treated patients vs expected 28-29% per year in natural history, suggesting slowed disease progression.","Three of eight patients had four SAEs, including new pulmonary embolism in Dose 2 patient (Patient 8) possibly related; responded to anticoagulants.","Company plans to amend upliFT-D protocol to add prophylactic low-dose anticoagulation and restrict enrollment to earlier-stage patients; Patient 9 may proceed with extra monitoring.","Milestones: submit amendment July 2025; report Dose 2 interim data 1H 2026; seek regulatory feedback on registrational trial design 1H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-061371","json":"https://secwatch.observer/filing/0001104659-25-061371.json","markdown":"https://secwatch.observer/filing/0001104659-25-061371.md","text":"https://secwatch.observer/filing/0001104659-25-061371.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000110465925061371/0001104659-25-061371-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000110465925061371/tm2518584d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:58:58.279295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}